Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank44
5Y CAGR-40.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-40.7%/yr
Long-term compound
Percentile
P44
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.02% |
| Q3 2025 | 41.32% |
| Q2 2025 | 1031.47% |
| Q1 2025 | -93.73% |
| Q4 2024 | -16.71% |
| Q3 2024 | 257.50% |
| Q2 2024 | 999.25% |
| Q1 2024 | -103.25% |
| Q4 2023 | 66.89% |
| Q3 2023 | 817.38% |
| Q2 2023 | -108.12% |
| Q1 2023 | 699.83% |
| Q4 2022 | -124.89% |
| Q3 2022 | 174.55% |
| Q2 2022 | -264.41% |
| Q1 2022 | 20.68% |
| Q4 2021 | -23.19% |
| Q3 2021 | 258.60% |
| Q2 2021 | -135.06% |
| Q1 2021 | 39.80% |
| Q4 2020 | 136.64% |
| Q3 2020 | -75.02% |
| Q2 2020 | 265.60% |
| Q1 2020 | 196.34% |
| Q4 2019 | -136.37% |
| Q3 2019 | 563.27% |
| Q2 2019 | 119.46% |
| Q1 2019 | -141.75% |
| Q4 2018 | 317.92% |
| Q3 2018 | 163.02% |
| Q2 2018 | -464.72% |
| Q1 2018 | -58.59% |
| Q4 2017 | -11.22% |
| Q3 2017 | 182.73% |
| Q2 2017 | -62.54% |
| Q1 2017 | 90.82% |
| Q4 2016 | 0.00% |